PrimeC is now FDA-cleared to enter Phase III development in ALS, as competition in the indication intensifies with several ...

Blocking the NAD hydrolase may save axons from neurodegeneration, if researchers can figure out a safe way to do it ...

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage ...

Oral PrimeC for ALS significantly reduced toxic TDP-43 protein levels in a Phase 2b trial. PrimeC also slowed functional decline and extended survival by about 15 months. The treatment was well ...

SAN FRANCISCO--(BUSINESS WIRE)--Unlearn ®, a pioneering artificial intelligence company, today announced a groundbreaking partnership with German-based APST Research (APST), a leading platform for ALS ...

MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial in type 2 diabetes patients requires final two patients LA JOLLA, Calif., July 24, 2025 (GLOBE ...

Positive data from EXPERTS-ALS could accelerate RT1999 towards a registration trial; RT1999 to be presented as a poster at the MDA Conference MONTREAL, QUEBEC, CANADA ...

AMSTERDAM & BOSTON--(BUSINESS WIRE)--VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the first participant has been dosed in its ...

Former NFL running back Chris Johnson is bringing back the Ice Bucket Challenge to raise awareness and support for ...